Difference between revisions of "Rivaroxaban (Xarelto)"
Jump to navigation
Jump to search
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>") |
m |
||
| Line 9: | Line 9: | ||
*[http://www.janssenmedicalinformation.com/assets/pdf/products/files/Xarelto/pi/ENC-010330-11.pdf#page=9 Rivaroxaban (Xarelto) package insert PDF pages 9-10]<ref name="insert"></ref> | *[http://www.janssenmedicalinformation.com/assets/pdf/products/files/Xarelto/pi/ENC-010330-11.pdf#page=9 Rivaroxaban (Xarelto) package insert PDF pages 9-10]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/rivaroxaban-patient-drug-information Rivaroxaban (Xarelto) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rivaroxaban-patient-drug-information Rivaroxaban (Xarelto) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/rivaroxaban-patient-drug-information Rivaroxaban (Xarelto) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rivaroxaban-patient-drug-information Rivaroxaban (Xarelto) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 7/1/2011: Initial FDA approval | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Factor Xa inhibitors]] | ||
| + | |||
| + | [[Category:Hematology medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2011]] | ||
Revision as of 03:06, 3 November 2014
General information
Class/mechanism: Factor Xa inhibitor, acts at the active site of factor Xa to inhibit its actions in the coagulation cascade.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Rivaroxaban (Xarelto) package insert PDF pages 9-10[1]
- Rivaroxaban (Xarelto) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/1/2011: Initial FDA approval